Stock Analiz

Shoulder Innovations, Inc. SI

Medical/Dental Instruments · IPO 2025 · data as of November 13, 2026

$20.69Market cap $433M
Open the interactive analysis →

Shoulder Innovations, Inc. (SI) is a healthcare company listed in the US with a market value of about $433M. In the twelve months to September 30, 2026 it had revenue of $64M and net income of -$33M, a net margin of -51.7%.

Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is future growth (2/5); the weakest is value (0/5).

Key numbers: a 5-year average ROIC of -17%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 98% below the current price.

About Shoulder Innovations

Shoulder Innovations is listed in the US and classified in medical/dental instruments, IPO year 2025. It was profitable in 0 of the last 2 years in our data. It spends 16% of revenue on research and development.

Score: 1.0 / 5

Value0/5
Future growth2/5
Track record0/5
Financial health2/5
Shareholder returns1/5

Checks passed

  • Revenue growth above 10% last year
  • Strong R&D investment or growth above 20%
  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets
  • Stock-based pay below 5% of revenue

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • 3-year revenue growth above 10% a year
  • Profit margin improving
  • 3-year free cash flow growth above 10% a year

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S6.7
P/B3.7
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-9.9%
Shareholder yield0.0%
Intrinsic value vs. price−98%

Growth and quality

Revenue growth (1 yr)49.6%
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-67.3%
ROIC (5-yr avg.)-16.9%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 2 years

Fiscal yearTTM20252024
Revenue$64M$47M$32M
Net income-$33M-$40M-$16M
Free cash flow-$43M-$36M-$18M
EPS (diluted)$-1.61$-4.65$-242.04
Net margin-51.7%-85.3%-49.4%
ROIC—-16.9%—

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 4 analysts is $27.00, 30% above the current price; targets range from $25.00 to $28.00; the consensus rating is “Strong buy”; expected EPS is $-1.68 for the fiscal year ending December 31, 2026.

Frequently asked questions

Is Shoulder Innovations stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 98% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Shoulder Innovations pay a dividend?

Not currently.

Is Shoulder Innovations a good stock to buy?

We do not give buy or sell advice. Shoulder Innovations scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.